Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2021)

• Record Type: Journal Article
• Authors: Kosiborod, Mikhail N; Esterline, Russell; Furtado, Remo H M; Oscarsson, Jan; Gasparyan, Samvel B; Koch, Gary G; Martinez, Felipe; Mukhtar, Omar; Verma, Subodh; Chopra, Vijay; Buenconsejo, Joan; Langkilde, Anna Maria; Ambery, Philip; Tang, Fengming; Gosch, Kensey; Windsor, Sheryl L; Akin, Emily E; Soares, Ronaldo V P; Moia, Diogo D F; Aboudara, Matthew; Hoffmann Filho, Conrado Roberto; Feitosa, Audes D M; Fonseca, Alberto; Garla, Vishnu; Gordon, Robert A; Javaheri, Ali; Jaeger, Cristiano P; Leaes, Paulo E; Nassif, Michael; Pursley, Michael; Silveira, Fabio Serra; Barroso, Weimar Kunz Sebba; Lazcano Soto, José Roberto; Nigro Maia, Lilia; Berwanger, Otavio;
• Is Part Of: Lancet. Volume 9:Issue 9(2021)
• Page Start: 586
• Page End: 594
• Publication Date: 2021-09
• Subjects: Diabetes -- Periodicals; Endocrinology -- Periodicals; Endocrine glands -- Diseases -- Periodicals; 616.4
• DOI: 10.1016/S2213-8587(21)00180-7
• Languages: English
• ISSNs: 2213-8587

Abstract

Summary: Background: COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness. Methods: DARE-19 was a randomised, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (ie, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease). Patients critically ill at screening were excluded. Patients were randomly assigned 1:1 to dapagliflozin (10 mg daily orally) or matched placebo for 30 days. Dual primary outcomes were assessed in the intention-to-treat population: the outcome of prevention (time to new or worsened organ dysfunction or death), and the hierarchial composite outcome of recovery (change in clinical status by day 30). Safety outcomes, in patients who received at least one study medication dose, included serious adverse events, adverse events leading to discontinuation, and adverse events of interest. This study is registered with ClinicalTrials.gov, NCT04350593 . Findings: Between April 22, 2020 and Jan 1, 2021, 1250 patients were randomly assigned with 625 in each group. The primary composite outcome of prevention showed organ dysfunction or death occurred in 70 patients (11·2%) in the dapagliflozin group, and 86 (13·8%) in the placebo group (hazard ratio [HR] 0·80, 95% CI 0·58–1·10; p=0·17). For the primary outcome of recovery, 547 patients (87·5%) in the dapagliflozin group and 532 (85·1%) in the placebo group showed clinical status improvement, although this was not statistically significant (win ratio 1·09, 95% CI 0·97–1·22; p=0·14). There were 41 deaths (6·6%) in the dapagliflozin group, and 54 (8·6%) in the placebo group (HR 0·77, 95% CI 0·52–1·16). Serious adverse events were reported in 65 (10·6%) of 613 patients treated with dapagliflozin and in 82 (13·3%) of 616 patients given the placebo. Interpretation: In patients with cardiometabolic risk factors who were hospitalised with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated. Funding: AstraZeneca.